Rakuten Medical, Inc.
900 Concar Dr, Suite 200
Tel: (858) 925-5619
About Rakuten Medical, Inc.
Rakuten Medical, Inc. is a global biotechnology company developing precision, cell-targeting investigational therapies on its IlluminoxTM technology platform, which, in pre-clinical studies have been shown to induce rapid and selective cell killing and tumor necrosis. Illuminox therapies have not yet been approved as safe or effective by any regulatory authority. The company's first investigational product developed on the Illuminox platform, ASP-1929, has achieved Fast Track designation from the FDA and Sakigake Designation from the Japanese Ministry of Health, Labour, and Welfare, and is currently the subject of a global phase 3 clinical trial for recurrent head and neck cancer. Rakuten Medical is committed to its mission to conquer cancer and aims to realize a society where cancer patients can lead fulfilling lives. Headquartered in the United States, Rakuten Medical has 6 locations in 5 countries, Japan, the Netherlands, Germany and Taiwan. For more information, visit www.rakuten-med.com.
29 articles with Rakuten Medical, Inc.
Rakuten Aspyrian today announced that it has raised an additional $134 million in a second tranche of its Series C financing, bringing the total amount raised to $284 million.
Rakuten Aspyrian, announced that enrollment is underway in its global, pivotal Phase 3 clinical trial evaluating lead product candidate ASP-1929 in patients with recurrent local regional head and neck squamous cell carcinomas (HNSCC).
Rakuten Aspyrian today announced the appointment of Mickey Mikitani as chief executive officer.
8/24/2018San Diego-based Rakuten Aspyrian nabbed $150 million in a Series C financing round. The funding provides the company with a total of $238 million in equity. Rakuten Aspyrian will use the funds to drive its lead therapy into Phase III trials.
Funds will support pivotal Phase 3 trial of ASP-1929 in head and neck cancer and additional pipeline expansion to treat other tumor types
Aspyrian Therapeutics Announces Successful Advances in RM-1929 Clinical Development in Recurrent Head and Neck Cancer, Including Fast Track Designation Granted by the FDA
RM-1929 is currently being tested in an ongoing Phase 2 study in recurrent Head and Neck cancer.
Aspyrian Therapeutics Closes $15.1M As Part Of A Series B-1 Financing To Support The Advancement Of Its Proprietary Precision Targeted Therapy, RM-1929, To Late Stage Clinical Development And The Progression Of New Proprietary Immune Oncology Assets Into
Aspyrian Therapeutics Announces The Presentation Of Clinical Data Of Its Investigational Therapy Rm-1929 Demonstrating Significant Anti-Cancer Response In Recurrent Head And Neck Cancer Patients Who Have Failed All Existing Treatment Options
Aspyrian Therapeutics Closes A $40M Series B Financing To Advance The Precision Targeted Cancer Therapy, RM-1929, To Late Stage Clinical Development In Recurrent Head And Neck Cancer And Other Cancer Areas